Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice

Masamune Mitsumoto, Toshiharu Kamura, Hiroaki Kobayashi, Takanori Sonoda, Tsunehisa Kaku, Hitoo Nakano

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To establish a more suitable model for reflecting biological aggressiveness in clinically recurrent cancers after chemotherapy, we made the in-vitro-established cisplatin-resistant cell lines, by exposing the parental tumor cell lines to cisplatin in a culture system, and also the in- vivo-established cisplatin-resistant cell lines by repeated cisplatin administration to parental tumor-bearing mice. Although both cell lines similarly demonstrated a clinically relevant low level of drug resistance (from 1.5 to 2.9 times more resistance to cisplain than their parental cell lines), only the in-vivo-established cisplain-resistant cell lines showed significantly enhanced metastatic properties with a 2.1- to 3.4-fold increase in the number of lung metastatic nodules. These enhanced metastatic properties were caused by tumor invasiveness in combination with various levels of enhancement of cell attachment, proteolytic enzyme activity and cell motility. We concluded that anticancer drugs such as cisplatin could promote tumor progression only in the drug-resistant cell lines established in vivo. As a result, these cell lines are considered to be a more faithful and useful model for expressing biological aggressiveness in clinically recurrent cancers after chemotherapy than the conventional drug-resistant cell lines established in vitro.

Original languageEnglish
Pages (from-to)607-614
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume124
Issue number11
DOIs
Publication statusPublished - Dec 16 1998

Fingerprint

Cisplatin
Cell Line
Pharmaceutical Preparations
Neoplasms
Biological Models
Drug Therapy
Tumor Cell Line
Drug Resistance
Cell Movement
Peptide Hydrolases
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice. / Mitsumoto, Masamune; Kamura, Toshiharu; Kobayashi, Hiroaki; Sonoda, Takanori; Kaku, Tsunehisa; Nakano, Hitoo.

In: Journal of Cancer Research and Clinical Oncology, Vol. 124, No. 11, 16.12.1998, p. 607-614.

Research output: Contribution to journalArticle

Mitsumoto, Masamune ; Kamura, Toshiharu ; Kobayashi, Hiroaki ; Sonoda, Takanori ; Kaku, Tsunehisa ; Nakano, Hitoo. / Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice. In: Journal of Cancer Research and Clinical Oncology. 1998 ; Vol. 124, No. 11. pp. 607-614.
@article{73ffcbd770e1497d8ffc776259449d7e,
title = "Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice",
abstract = "To establish a more suitable model for reflecting biological aggressiveness in clinically recurrent cancers after chemotherapy, we made the in-vitro-established cisplatin-resistant cell lines, by exposing the parental tumor cell lines to cisplatin in a culture system, and also the in- vivo-established cisplatin-resistant cell lines by repeated cisplatin administration to parental tumor-bearing mice. Although both cell lines similarly demonstrated a clinically relevant low level of drug resistance (from 1.5 to 2.9 times more resistance to cisplain than their parental cell lines), only the in-vivo-established cisplain-resistant cell lines showed significantly enhanced metastatic properties with a 2.1- to 3.4-fold increase in the number of lung metastatic nodules. These enhanced metastatic properties were caused by tumor invasiveness in combination with various levels of enhancement of cell attachment, proteolytic enzyme activity and cell motility. We concluded that anticancer drugs such as cisplatin could promote tumor progression only in the drug-resistant cell lines established in vivo. As a result, these cell lines are considered to be a more faithful and useful model for expressing biological aggressiveness in clinically recurrent cancers after chemotherapy than the conventional drug-resistant cell lines established in vitro.",
author = "Masamune Mitsumoto and Toshiharu Kamura and Hiroaki Kobayashi and Takanori Sonoda and Tsunehisa Kaku and Hitoo Nakano",
year = "1998",
month = "12",
day = "16",
doi = "10.1007/s004320050222",
language = "English",
volume = "124",
pages = "607--614",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice

AU - Mitsumoto, Masamune

AU - Kamura, Toshiharu

AU - Kobayashi, Hiroaki

AU - Sonoda, Takanori

AU - Kaku, Tsunehisa

AU - Nakano, Hitoo

PY - 1998/12/16

Y1 - 1998/12/16

N2 - To establish a more suitable model for reflecting biological aggressiveness in clinically recurrent cancers after chemotherapy, we made the in-vitro-established cisplatin-resistant cell lines, by exposing the parental tumor cell lines to cisplatin in a culture system, and also the in- vivo-established cisplatin-resistant cell lines by repeated cisplatin administration to parental tumor-bearing mice. Although both cell lines similarly demonstrated a clinically relevant low level of drug resistance (from 1.5 to 2.9 times more resistance to cisplain than their parental cell lines), only the in-vivo-established cisplain-resistant cell lines showed significantly enhanced metastatic properties with a 2.1- to 3.4-fold increase in the number of lung metastatic nodules. These enhanced metastatic properties were caused by tumor invasiveness in combination with various levels of enhancement of cell attachment, proteolytic enzyme activity and cell motility. We concluded that anticancer drugs such as cisplatin could promote tumor progression only in the drug-resistant cell lines established in vivo. As a result, these cell lines are considered to be a more faithful and useful model for expressing biological aggressiveness in clinically recurrent cancers after chemotherapy than the conventional drug-resistant cell lines established in vitro.

AB - To establish a more suitable model for reflecting biological aggressiveness in clinically recurrent cancers after chemotherapy, we made the in-vitro-established cisplatin-resistant cell lines, by exposing the parental tumor cell lines to cisplatin in a culture system, and also the in- vivo-established cisplatin-resistant cell lines by repeated cisplatin administration to parental tumor-bearing mice. Although both cell lines similarly demonstrated a clinically relevant low level of drug resistance (from 1.5 to 2.9 times more resistance to cisplain than their parental cell lines), only the in-vivo-established cisplain-resistant cell lines showed significantly enhanced metastatic properties with a 2.1- to 3.4-fold increase in the number of lung metastatic nodules. These enhanced metastatic properties were caused by tumor invasiveness in combination with various levels of enhancement of cell attachment, proteolytic enzyme activity and cell motility. We concluded that anticancer drugs such as cisplatin could promote tumor progression only in the drug-resistant cell lines established in vivo. As a result, these cell lines are considered to be a more faithful and useful model for expressing biological aggressiveness in clinically recurrent cancers after chemotherapy than the conventional drug-resistant cell lines established in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0031744116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031744116&partnerID=8YFLogxK

U2 - 10.1007/s004320050222

DO - 10.1007/s004320050222

M3 - Article

C2 - 9860289

AN - SCOPUS:0031744116

VL - 124

SP - 607

EP - 614

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 11

ER -